Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth A Raetz

Showing results (41-50 of 155) with videos related to

Pageof 16
Sort By:
Haematologica|December 23, 2021
Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemiaKaren L Bride, Hai Hu, Anastasia Tikhonova, et al.
Journal of Pediatric Hematology/Oncology|November 27, 2013
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumElizabeth A Raetz, Debra Morrison, Eleny Romanos-Sirakis, et al.
Blood|September 15, 2022
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 studyLuke Maese, Mignon L Loh, Mi Rim Choi, et al.
British Journal of Haematology|July 5, 2014
Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemiaSmita Dandekar, Eleny Romanos-Sirakis, Faye Pais, et al.
Nature Communications|August 28, 2024
Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemiaSonali Narang, Yohana Ghebrechristos, Nikki A Evensen, et al.
Pediatric Blood & Cancer|November 2, 2017
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology GroupRachel E Rau, ZoAnn Dreyer, Mi Rim Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot StudyElizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Pediatric Blood & Cancer|August 8, 2023
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1)Elizabeth A Raetz, David T Teachey, Charles Minard, et al.
Ejhaem|August 21, 2023
SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731Caitlin W Elgarten, John A Kairalla, Joel C Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2020
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology GroupSumit Gupta, Cindy Wang, Elizabeth A Raetz, et al.
Pageof 16

Showing results (41-50 of 155) with videos related to

Sort By:
Pageof 16
Haematologica|December 23, 2021
Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemiaKaren L Bride, Hai Hu, Anastasia Tikhonova, et al.
Journal of Pediatric Hematology/Oncology|November 27, 2013
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumElizabeth A Raetz, Debra Morrison, Eleny Romanos-Sirakis, et al.
Blood|September 15, 2022
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 studyLuke Maese, Mignon L Loh, Mi Rim Choi, et al.
British Journal of Haematology|July 5, 2014
Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemiaSmita Dandekar, Eleny Romanos-Sirakis, Faye Pais, et al.
Nature Communications|August 28, 2024
Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemiaSonali Narang, Yohana Ghebrechristos, Nikki A Evensen, et al.
Pediatric Blood & Cancer|November 2, 2017
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology GroupRachel E Rau, ZoAnn Dreyer, Mi Rim Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot StudyElizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Pediatric Blood & Cancer|August 8, 2023
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1)Elizabeth A Raetz, David T Teachey, Charles Minard, et al.
Ejhaem|August 21, 2023
SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731Caitlin W Elgarten, John A Kairalla, Joel C Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2020
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology GroupSumit Gupta, Cindy Wang, Elizabeth A Raetz, et al.
Pageof 16